Vascular and Metabolic Effects of Omega-3 Fatty Acids
Primary Purpose
Hypertriglyceridemia
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
placebo
omega
Sponsored by
About this trial
This is an interventional treatment trial for Hypertriglyceridemia focused on measuring insulin resistance
Eligibility Criteria
Inclusion Criteria:
- hypertriglyceridemia
Exclusion Criteria:
- overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c > 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse
Sites / Locations
- Gil Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
placebo
omega 1
omega 2
omega 4
Arm Description
placebo
omega 1 gm
omega 2 gm
omega 4 gm
Outcomes
Primary Outcome Measures
flow-mediated dilation
Secondary Outcome Measures
insulin resistance
Full Information
NCT ID
NCT01660932
First Posted
August 8, 2012
Last Updated
November 1, 2014
Sponsor
Gachon University Gil Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01660932
Brief Title
Vascular and Metabolic Effects of Omega-3 Fatty Acids
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gachon University Gil Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators hypothesize that omega does-dependently improves vascular and insulin resistance.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertriglyceridemia
Keywords
insulin resistance
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
176 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo
Arm Title
omega 1
Arm Type
Active Comparator
Arm Description
omega 1 gm
Arm Title
omega 2
Arm Type
Active Comparator
Arm Description
omega 2 gm
Arm Title
omega 4
Arm Type
Active Comparator
Arm Description
omega 4 gm
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Type
Drug
Intervention Name(s)
omega
Primary Outcome Measure Information:
Title
flow-mediated dilation
Time Frame
8 weeks of treatment
Secondary Outcome Measure Information:
Title
insulin resistance
Time Frame
8 weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hypertriglyceridemia
Exclusion Criteria:
overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c > 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse
Facility Information:
Facility Name
Gil Medical Center
City
Incheon
ZIP/Postal Code
405-760
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Vascular and Metabolic Effects of Omega-3 Fatty Acids
We'll reach out to this number within 24 hrs